StreetInsider.com News Articles

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of psychedelics and peptides, today announced a strategic initiative to expand its PharmaPatch™ microneedle patch platform into select therapeutic peptides for the U.S. market, building on the Company's ketamine and psychedelics patch development achievements and its recent entry into GLP-1 delivery using PharmaPatch™.

"Building on our ketamine and psychedelics patch programs and our expansion into GLP-1 delivery, we are now broadening PharmaPatch™ to evaluate select peptide candidates where a needle-free, at-home patch could

PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market

Tue, 03 Mar 2026 08:00:00 +0000

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Mon, 02 Feb 2026 09:27:00 +0000

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering execution, including its U.S. FDA approval of ketamine and the monetization of U.S. rights with potential proceeds exceeding US$25 million.

Canada Opens as an Early Major Market for Generic Semaglutide

In January 2026, regulatory exclusivity for semaglutide in

PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success

Mon, 02 Feb 2026 09:27:00 +0000

Canada Opens as an Early Major Market for Generic Semaglutide

In January 2026, regulatory exclusivity for semaglutide in

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Wed, 14 Jan 2026 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for the potential treatment of obesity.

PharmaTher's decision to enter the obesity market builds on the Company's successful development progress with its ketamine and multiple psychedelic compounds patch programs, including pre-IND-enabling work and published research demonstrating controlled, sustained delivery and flexible patch design principles.^1-6

"PharmaTher built

PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs

Wed, 14 Jan 2026 08:00:00 +0000

"PharmaTher built

PharmaTher CEO Publishes Letter to Shareholders

Fri, 02 Jan 2026 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.

Dear Shareholders,

With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.

PharmaTher's strategy is clear: to acquire and advance assets that can be efficiently monetized to generate product revenue, royalty income, equity value, and strategic partnerships. We currently manage two assets: our ketamine franchise

PharmaTher CEO Publishes Letter to Shareholders

Fri, 02 Jan 2026 08:00:00 +0000

Dear Shareholders,

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Tue, 02 Dec 2025 09:53:00 +0000

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced it has closed the previously announced sale of its Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP to a leading sterile-injectables pharmaceutical company.

At closing, PharmaTher received a confidential upfront cash payment and remains eligible to receive additional milestone payments based on cumulative sales thresholds, as well as profit-sharing payments for seven years following first commercial sale. In total, the transaction

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

Tue, 02 Dec 2025 09:53:00 +0000

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Mon, 17 Nov 2025 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced that it has entered into an Exclusive Evaluation and Option-to-License Agreement (the "Agreement") with Oakwood Laboratories, LLC ("Oakwood") for the development and commercialization of Oakwood's patented long-acting injectable ("LAI") ketamine program.

Fabio Chianelli, Chairman and CEO of PharmaTher, commented: "The long-acting ketamine program is a pivotal step in our strategy to build the most comprehensive ketamine franchise in neuropsychiatric disorders. We believe a convenient, durable

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

Mon, 17 Nov 2025 08:00:00 +0000

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Fri, 17 Oct 2025 08:26:00 +0000

Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a critical drug for general anesthesia." The pilot elevates ketamine as a national priority.

The CNPV is expected to a catalyst for the ketamine market—and PharmaTher is positioned at the forefront. By prioritizing ketamine,

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

Fri, 17 Oct 2025 08:26:00 +0000

The CNPV is expected to a catalyst for the ketamine market—and PharmaTher is positioned at the forefront. By prioritizing ketamine,

PharmaTher prepares FDA package for ketamine Phase 3 Parkinson's study

Thu, 16 Oct 2025 08:04:11 +0000

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced it is preparing FDA briefing materials for a Phase 3 program testing ketamine in levodopa-induced dyskinesia in Parkinson's disease, according to a company statement.

The Toronto-based specialty life sciences company is developing a Pre-Phase 3 FDA package to confirm registrational study design for a 505(b)(2) New Drug Application. The company stated that prior FDA feedback indicated a single, well-controlled trial may be sufficient in appropriate settings.

Previous Phase I/II data showed dyskinesia reductions on the UDysRS scale at multiple time points, with 51% reduction during Infusion 2, 49% at 3 weeks, and 41% at

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

Thu, 16 Oct 2025 08:00:00 +0000

Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoing

Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced that it has begun preparing its U.S. Food and Drug Administration ("FDA") briefing materials to discuss a Phase 3 program for ketamine in levodopa-induced dyskinesia in Parkinson's disease ("LID-PD") and that prospective pharma partners are currently evaluating potential collaboration structures for the registrational program and commercialization.

Key Updates

PharmaTher is preparing

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

Thu, 16 Oct 2025 08:00:00 +0000

Company preparing FDA meeting package to align on a single, well-controlled Phase 3 study under 505(b)(2); Pharma partner discussions ongoing

Key Updates

PharmaTher is preparing

PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

Wed, 15 Oct 2025 08:00:00 +0000

Expanding ketamine indications, fortifying IP, enabling earlier partnerships, and accelerating FDA pathways - underpinned by PharmaTher's Digital Health AI division, leveraging the Company's FDA-approved ketamine ANDA CMC and KetaVault(TM) data advantage.

Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced KetAImine™, a proprietary ketamine repurposing and discovery platform designed to create, prioritize, and de-risk new ketamine indications and combination therapies across therapeutic areas—forming a scalable pipeline for partnering opportunities and NDA submissions via the 505(b)(2) pathway. KetAImine™ complements

PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

Wed, 15 Oct 2025 08:00:00 +0000

PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

Wed, 08 Oct 2025 08:00:00 +0000

Phase 3 program targeting a potential US$2.2B U.S. market opportunity
505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and time
FDA-reviewed CMC package validated through prior ANDA approval
Patent coverage to 2036 for ketamine in Parkinson's and related motor disorders
Active pharmaceutical partnering discussions
Upcoming catalysts (Q4 2025 - Q2 2026): FDA meeting, pivotal study readiness, pharma partnership

Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, today announced an update regarding its initiative to develop ketamine as a treatment for

PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

Wed, 08 Oct 2025 08:00:00 +0000

Phase 3 program targeting a potential US$2.2B U.S. market opportunity
505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and time
FDA-reviewed CMC package validated through prior ANDA approval
Patent coverage to 2036 for ketamine in Parkinson's and related motor disorders
Active pharmaceutical partnering discussions
Upcoming catalysts (Q4 2025 - Q2 2026): FDA meeting, pivotal study readiness, pharma partnership

PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative

Wed, 27 Aug 2025 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, today announced the advancement of its ketamine transdermal patch as a next-generation, non-opioid pain relief solution, building on the recent FDA approval of its IV ketamine product (KETARx™).

"With KETARx™ now FDA-approved, our next chapter is to expand ketamine's impact through an innovative transdermal patch that can redefine pain management," said Fabio Chianelli, Founder and CEO of PharmaTher. "By addressing the unmet medical need for effective non-opioid pain relief, targeting a

PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative

Wed, 27 Aug 2025 08:00:00 +0000

PharmaTher receives FDA approval for ketamine product KETARx

Thu, 14 Aug 2025 08:02:11 +0000

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) announced that it received FDA approval for its ketamine product KETARx on August 8, 2025, for use in surgical pain management including anesthesia and sedation.

The specialty pharmaceutical company, which focuses on ketamine-based treatments, disclosed the approval through a shareholder letter from founder and CEO Fabio Chianelli. The company publicly announced the milestone on August 11, 2025.

PharmaTher is proceeding with pre-launch commercialization activities in the United States while preparing international regulatory filings. The company plans to target hospitals, specialty clinics, and government institutions including the U.S. Department of Defense and Veterans Health Administration as

PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))

Thu, 14 Aug 2025 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, announced today that Fabio Chianelli, the Company's Founder, Chairman and Chief Executive Officer, has issued the following letter to shareholders.

Dear Fellow Shareholders,

Earlier this year, I wrote to you about the challenges we faced with our FDA Priority Original Abbreviated New Drug Application for our ketamine product, which we have named KETARx™. I was thrilled to receive the FDA approval letter on Friday, August 8, 2025, for KETARx™, for